Skip to main content
. 2019 Mar 6;20(5):1139. doi: 10.3390/ijms20051139

Figure 2.

Figure 2

Specific suppression of epithelial ovarian cancer cell lines (HTB75 and OVCAR3), and a melanoma cell line (A375) by expanded Vγ9Vδ2 T-cells alone. (A) Standard 24-h cytotoxicity activities were performed with many replicates (n > 12) with increasing effector (Vγ9Vδ2 T-cells) concentrations to target E/T ratios of 0, 0.1, 1, 10, and 20 against the cancer cell lines: OVCAR3, HTB75, SKOV3, TOV112D, A2780 and A375. Cytotoxic activities were compared to the Pamidronate (PAM) treated alone, Vγ9Vδ2 T-cells + anti-NKG2D mAb, Vγ9Vδ2 T-cells + PAM (2μg/mL) treated, and activated αβ T-cell- and naïve CD3+ T-cell-treated served as the controls of Vγ9Vδ2 T-cells (n = 12–20; significance range at * p = 0.035 ~ **** p < 0.0001). (B) Real-time monitoring of cytotoxic activities were compared to the PAM (2μg/mL) treated alone, Vγ9Vδ2 T-cells + PAM (2μg/mL) treated, and Triton X-100 (1%) treated served as the positive control. Real-time monitoring of γδ T- cell-treated alone induced growth inhibition of epithelial-type cells: OVCAR3, HTB75, whereas combination of Vγ9Vδ2-T cells + PAM treatment enhanced growth inhibition of all the cells, including OVCAR3, HTB75, A375 and SKOV3 using the x-CELLigence system. Data are presented as the mean ± SD of three independent experiments.